Table 3.
Modifications in Metabolic Syndrome factors: control group and experimental group
| Control Group (n = 21) | Intervention Group (n = 23) | |||||||
|---|---|---|---|---|---|---|---|---|
| Variables | Basal | 6 months | p | Basal | 6 months | p | P* | P** |
| Biochemical profile | ||||||||
| - Glucose (mg/dL) | 94.5 (16.8) | 102.6 (18.9) | 0.03 | 93.7 (10.4) | 97.5 (13.5) | 0.023 | 0.814 | 0.259 |
| - HbA1c (%) | 5.4 (0.4) | 5.5 (0.3) | 0.038 | 5.4 (0.3) | 5.4 (0.6) | 0.948 | 0.887 | 0.768 |
| - Cholesterol (mg/dL) | 173.2 (45.4) | 171 (43.9) | 0.664 | 199.1 (38.4) | 179.4 (64.3) | 0.072 | 0.115 | 0.155 |
| - Triglycerides (mg/dL) | 121.1 (67.4) | 137.5 (75.8) | 0.352 | 141.1 (74.3) | 134.2 (69.4) | 0.584 | 0.235 | 0.981 |
| - LDH (IU/L) | 182.5 (22.5) | 172.4 (29.9) | 0.141 | 189 (30.6) | 172.4 (29.9) | 0.049 | 0.533 | 0.647 |
| - C-HDL (mg/dL) | 50.2 (15.4) | 48.4 (15.1) | 0.067 | 49.7 (13.1) | 52.4 (24.9) | 0.611 | 0.962 | 0.760 |
| - C-LDL (mg/dL) | 100.4 (33.8) | 96.9 (33.7) | 0.446 | 123 (32.4) | 119.3 (41.6) | 0.7 | 0.048 | 0.067 |
| - Total cholesterol/C-HDL (mg/dL) | 3.6 (0.9) | 3.6 (0.8) | 0.522 | 4.2 (1.3) | 4.2 (1.3) | 0.905 | 0.058 | 0.180 |
| Anthropometric Profile | ||||||||
| - Weight (kg) | 76.6 (18) | 75.8 (17.7) | 0.382 | 85.7 (16.3) | 81.3 (14.6) | < 0.001 | 0.086 | 0.275 |
| - Waist circumference (cm) | 100.9 (13.3) | 101.2 (13.5) | 0.818 | 105.7 (11.5) | 102 (11.7) | < 0.001 | 0.397 | 0.981 |
| - BMI (kg/m2) | 27.5 (5.2) | 27.2 (5.3) | 0.323 | 29.5 (4.8) | 27.9 (4.3) | < 0.001 | 0.307 | 0.869 |
| - WHtR | 0.59 (0.12) | 0.61 (0.07) | 0.345 | 0.61 (0.07) | 0.59 (0.06) | < 0.001 | 0.597 | 0.378 |
| Cardiovascular Profile | ||||||||
| - SBP (mmHg) | 125.5 (16.3) | 129.8 (11.2) | 0.124 | 128.7(13.9) | 126.8 (10.6) | 0.593 | 0.391 | 0.359 |
| - DBP (mmHg) | 85.5 (9.7) | 82.3 (7.9) | 0.846 | 85.6 (11.5) | 80.8 (7.5) | 0.039 | 0.548 | 0.814 |
| - HR (bpm) | 88.5 (16.4) | 87.4 (14.2) | 0.757 | 81.4 (12) | 80.8 (9.4) | 0.792 | 0.110 | 0.226 |
p: intragroup statistical significance; p*: baseline intergroup statistical significance; p**: 6 months intergroup statistical significance; HbA1c Glycosylated haemoglobin, LDH Lactate dehydrogenase, C-HDL High-density lipoprotein, C-LDL Low-density lipoprotein, BMI Body mass index, WHtR Waist-to-height ratio, SBP Systolic blood pressure, DBP Diastolic blood pressure, HR Heart rate, CG Evol. Control group evolution, IG Evol Intervention group evolution, % Balance Percentage variation, REGICOR Calculation of 10-year coronary heart disease risk, SCORE Systematic coronary risk assessment for Spain, Antipsychotic DDD Defined daily dose antipsychotics